

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol							ing Syml	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
LEONHARDT HARRY J					HALOZYME THERAPEUTICS INC [HALO]							JTICS	Director		10	% Owner		
(Last)	(First)	t) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							_X_Officer (g SVP, GC and		ow)	Other (speci	fy below)	
C/O HALOZ INC., 11388									2/2	2/20	17							
ROAD			LLEI															
	(Stre	et)			4. I	f An	nendme	nt, Da	ate C	rigin	al Fi	led (MM/I	DD/YYYY)	6. Individual o	or Joint/G	roup Filing	(Check Appl	icable Line)
SAN DIEGO, CA 92121 (City) (State) (Zip)													X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(C	ity) (Sta	, , , ,		Non-	Der	ivati	ve Secu	ırities	s Ac	quire	ed, D	isposed	of, or Be	neficially Own	ed			
1. Title of Security (Instr. 3) 2. Trans. I]	Date 2A. Deemed Execution Date, if any Code 23. Trans. Code				or Disposed of (D) Follows			Amount of Securities Beneficially Owned llowing Reported Transaction(s) sstr. 3 and 4)			Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	Tabl	le II - Deri	vative So	ecurit	ies E	Bene	ficially	Own	ed (e.g. ,	puts	, calls, w	arrants,	options, conve	rtible sec	urities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deem- Execution Date, if an				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date			Underlying Security		derivative Securities Beneficially Owned Following	Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				C	ode	V	(A)			Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	
Option to Purchase Common Stock	\$12.07	2/22/2017		A	4		72925			2/22/2 (1		2/22/2027	Common Stock	72925	\$0	72925	D	
Restricted Stock Units	\$0	2/22/2017		A	4		45568			2/22/2 (2		<u>(2)</u>	Common Stock	45568	\$0	45568	D	

Explanation of Responses:

- (1) This option vests one-fourth on such date and then 1/48th monthly thereafter.
- (2) This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LEONHARDT HARRY J C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121			SVP, GC and CCO				

Signatures

/s/ James R. Oehler as attorney-in-fact for Harry J. Leonhardt	2/24/2017
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.